BTG (Bio-Technology General) starts imaging agent trials:
This article was originally published in Clinica
Bio-Technology General will begin Canadian trials of its agent for imaging potentially dangerous blood clots in deep-vein thrombosis. Fibrimage, a Technetium-99m radiopharmaceutical, is based on a recombinant polypeptide with high binding affinity for fibrin and the primary component of venous thrombus. The New Jersey-based company said the trial, involving at least 48 patients, would be completed before the end of the year.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.